Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ 42 and T-Tau assays for Alzheimer’s disease diagnosis

Background Cerebrospinal fluid (CSF) biomarkers are increasingly used to diagnose Alzheimer’s disease (AD). However, important methodological and technical remain regarding measurement variability between kit providers and users. We compared the Lumipulse fully automated assays with the manual INNOTEST assays (both from Fujirebio Europe NV, Gent, Belgium) on a clinically representative sample of patients and controls.